165 related articles for article (PubMed ID: 2942244)
1. Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.
Sigman LM; Van Echo DA; Egorin MJ; Whitacre MY; Aisner J
Cancer Treat Rep; 1986 Jun; 70(6):721-5. PubMed ID: 2942244
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of menogaril in patients with advanced cancer.
Brown TD; Donehower RC; Grochow LB; Rice AP; Ettinger DS
J Clin Oncol; 1987 Jan; 5(1):92-9. PubMed ID: 2949065
[TBL] [Abstract][Full Text] [Related]
3. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
Egorin MJ; Conley BA; Forrest A; Zuhowski EG; Sinibaldi V; Van Echo DA
Cancer Res; 1987 Nov; 47(22):6104-10. PubMed ID: 2959359
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic.
Dorr FA; Von Hoff DD; Kuhn JG; Schwartz R; Kisner DL
Cancer Res; 1986 May; 46(5):2562-5. PubMed ID: 2938729
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion.
Long HJ; Powis G; Schutt AJ; Moertel CG
Cancer Treat Rep; 1987 Jun; 71(6):593-8. PubMed ID: 2953414
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of oral menogaril administered on three consecutive days.
Dodion P; de Valeriola D; Crespeigne N; Peeters B; Wery F; van Berchem C; Joggi J; Kenis Y
Acta Oncol; 1988; 27(5):517-20. PubMed ID: 2974291
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of menogaril in advanced colorectal cancer.
Holdener EE; ten Bokkel Huinink WW; Decoster G; Ludwig C; Renard G; Pinedo HM
Invest New Drugs; 1988 Sep; 6(3):227-30. PubMed ID: 2973448
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days.
Dodion P; de Valeriola D; Crespeigne N; Peeters B; Wery F; van Berchem C; Piccart M; Tueni E; Joggi J; Kenis Y
Eur J Cancer Clin Oncol; 1988 Jun; 24(6):1019-26. PubMed ID: 2970391
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of intravenous menogaril administered intermittently.
Dodion P; Sessa C; Joss R; Crespeigne N; Willems Y; Kitt M; Abrams J; Finet C; Brewer JE; Adams WJ
J Clin Oncol; 1986 May; 4(5):767-74. PubMed ID: 2939203
[TBL] [Abstract][Full Text] [Related]
12. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
13. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A
Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of oral menogaril administered on a once weekly schedule.
Stewart DJ; Verma S; Maroun JA; Robillard L; Earhart RH
Invest New Drugs; 1990 Feb; 8(1):43-52. PubMed ID: 2140564
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of oral menogaril administered daily for 14 consecutive days.
Stewart DJ; Aitken SE; Verma S; Maroun JA; Robillard L; Touchie M; Prosser IA; Earhart R
Ann Oncol; 1992 May; 3(5):401-3. PubMed ID: 1535508
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of intravenous menogaril in patients with advanced breast cancer.
Sessa C; Gundersen S; ten Bokkel Huinink W; Renard J; Cavalli F
J Natl Cancer Inst; 1988 Sep; 80(13):1066-9. PubMed ID: 2970554
[TBL] [Abstract][Full Text] [Related]
18. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of weekly intravenous administration of menogaril to adults with solid tumors.
Stewart DJ; Maroun JA; Verma S; Perrault D; Earhart RH
Am J Clin Oncol; 1989 Dec; 12(6):511-8. PubMed ID: 2531540
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of intravenous menogaril in advanced ovarian carcinoma. EORTC Early Clinical Trials Group.
Sessa C; Kaye SB; Renard J; ten Bokkel Huinink W; Cavalli F
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):751-2. PubMed ID: 2523809
[No Abstract] [Full Text] [Related]
[Next] [New Search]
